Tickernomics

10y

Historical Returns*:

SPY

27.80%

-32.10%

BBIO

SPY

32.66%

BBIO

111.39%

SPY

108.59%

-22.94%

BBIO

SPY

302.52%

BBIO

0.00%

*Assumes dividends reinvested

Market Stats:

Market Capitalization($MM)

Enterprise Value($MM)

Daily Volume(MM)

4993.64

5168.14

1.03

Valuation Metrics:

Price/Earnings Ratio

Price/Sales Ratio

Price/Book Value

FCF Yield(%)

Dividend Yield(%)

EV/EBITDA

-11.38

22.93

-4.10

-9.74

0.00

-9.35

Profitability Stats:

Operating Margin %(ttm)

Gross Profit %(ttm)

EBITDA Margin %(ttm)

-7018.67

78.11

-252.55

Shareholder Value Creation:

Cost of Capital %(est)

ROIC %(ttm)

ROCE %(ttm)

Beta

8.3312

-142.91

-123.59

1.09

Other Earnings and Cash Flow Stats:

BridgeBio Pharma Inc. ( BBIO ) Net Income TTM ($MM) is -438.86

BridgeBio Pharma Inc. ( BBIO ) Operating Income TTM ($MM) is -544.36

BridgeBio Pharma Inc. ( BBIO ) Owners' Earnings Annual ($MM) is 0.00

BridgeBio Pharma Inc. ( BBIO ) Current Price to Owners' Earnings ratio is 0.00

BridgeBio Pharma Inc. ( BBIO ) EBITDA TTM ($MM) is -538.07

BridgeBio Pharma Inc. ( BBIO ) EBITDA Margin is -252.55%

Capital Allocation:

BridgeBio Pharma Inc. ( BBIO ) has paid 0.00 dividends per share and bought back -25.20174 million shares in the past 12 months

BridgeBio Pharma Inc. ( BBIO ) has reduced its debt by 18.986 million USD in the last 12 months

Capital Structure:

BridgeBio Pharma Inc. ( BBIO ) Interest-bearing Debt ($MM) as of last quarter is 440

BridgeBio Pharma Inc. ( BBIO ) Annual Working Capital Investments ($MM) are -58

BridgeBio Pharma Inc. ( BBIO ) Book Value ($MM) as of last quarter is -1219

BridgeBio Pharma Inc. ( BBIO ) Debt/Capital as of last quarter is -36%

Other Balance Sheet Stats:

BridgeBio Pharma Inc. ( BBIO ) has 266 million in cash on hand as of last quarter

BridgeBio Pharma Inc. ( BBIO ) has 139 million of liabilities due within 12 months, and long term debt 436 as of last quarter

BridgeBio Pharma Inc. ( BBIO ) has 188 common shares outstanding as of last quarter

BridgeBio Pharma Inc. ( BBIO ) has 0 million USD of preferred stock value

Academic Scores:

BridgeBio Pharma Inc. ( BBIO ) Altman Z-Score is -6.26 as of last quarter

BridgeBio Pharma Inc. ( BBIO ) Piotroski Score is 4.00 as of last quarter

Corporate Governance:

BridgeBio Pharma Inc. ( BBIO ) largest shareholder is owning shares at 0.00 ($MM) value

Kumar Neil(an insider) Sold 1875 shares of BridgeBio Pharma Inc. ( BBIO ) for the amount of $42679.69 on 2024-11-19

5.40% of BridgeBio Pharma Inc. ( BBIO ) is held by insiders, and 94.46% is held by institutions

BridgeBio Pharma Inc. ( BBIO ) went public on 2019-06-27

About BridgeBio Pharma Inc. ( BBIO ) :

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.